Enzo Biochem’s Clinical Laboratory Applies for NY State Health Department Approval for First Assay Based on its AmpiProbe™ Amplification Platform
Published: Mar 13, 2012
NEW YORK--(BUSINESS WIRE)--Enzo Biochem Inc. (NYSE:ENZ) announced today the filing of an application with the New York State Department of Health for the first assay based on its proprietary AmpiProbe™ nucleic acid detection platform. Upon approval, the Company plans to market its HCV RNA Quantification Assay for viral load determination through its Enzo Clinical Laboratory. The Company previously announced plans to seek CE-IVD designation for this assay in order to make it available as a diagnostic product in the European Union.